Medical decision supporting method and system

Abstract

The invention discloses a medical decision supporting method, which comprises the following steps: configuring a risk decision information base in advance; utilizing the risk decision information base to test a patient, and determining the reaction results of the patient on the risk decision information of different expression modes; according to the reaction results, adopting latent class analysis to classify the potential risk decision tendencies of the patient, and predicting the thrombolysis identification rates of the patients in different classes for accepting the risk decision information of different expression modes; collecting the basic information of the patient from multiple dimensions; according to the class of the risk decision tendency of the patient and the multi-dimensional basic information of the patient, establishing a risk decision model to predict the intravenous thrombolysis tendency of the patient; and carrying out intravenous thrombolysis indication assessment on the patient, collecting the basic information of the patient according to the risk decision model if the patient conforms to the indication, substituting a thrombolysis risk decision model to predict the intravenous thrombolysis decision tendency of the patient, and finally, determining an expression mode of optimal intravenous thrombolysis decision information which is shown to the patient.

Description

technical field [0001] The present invention relates to the field of medical technology, in particular to a medical decision support method and system. Background technique [0002] Stroke (commonly known as apoplexy, including cerebral infarction and cerebral hemorrhage, 80-85% is cerebral infarction), is an acute cerebrovascular disease, which has the characteristics of high incidence rate, high disability rate, high mortality rate and high recurrence rate. Worldwide, stroke has become the second leading cause of death after cancer, and it is also the leading cause of death in our country. The incidence of stroke is increasing at a rate of 8.7% per year. [0003] Acute cerebrovascular disease not only has the characteristics of "four highs", which seriously threaten the health and survival of the people, but from the perspective of health economics, there is another "high", which is high economic burden. According to statistics, the cost of treating cerebrovascular diseas...

AI Technical Summary

Problems solved by technology

[0005] However, although intravenous rt-PA thrombolysis within the time window is the most effective and should be promoted in the treatment of acute cerebral infarction, due to time window restrictions and other factors, its use rate is very low worldwide. Recent reports in the United States show that Patients receiving thrombolytic therapy account for only 2.4% to 5.2% of all patients with acute cerebral infarction; while the rate of thrombolytic therapy in my country is even less than 1.6%.

[0008] Informed decision-making mode is affected by subjective factors of doctors and patients, which seriously affects the development of intravenous thrombolytic therapy

Although it has become a general consensus among medical workers to actively carry out thrombolytic therapy for eligible patients with acute cerebral infarction, for patients with cerebral infarction or their family members, they are facing serious problems: First, due to the usual promotion of stroke prevention Insufficient efforts, not only the awareness rate of thrombolytic therapy is low, but also there is a cognitive bias; secondly, once acute cerebral infarction occurs suddenly, when it is necessary to make a risk decision of thrombolysis, many patients and their families are faced with the following situations: Important information subject and source of risk notification; ②In current clinical practice, due to the lack of theoretical guidance on thrombolysis risk decision-making, there is no standardized operation process for decision-making in terms of decision-making form; in terms of decision-making content, there is no risk and The standardized content of benefits, thrombolysis risk decision-making can only rely on clinicians' personal understanding of intravenous thrombolysis, likes and dislikes, and communication habits, which is extremely subjective and arbitrary; Knowing bias, overly worried about the risk of thrombolytic hemorrhage and hesitation, missing the best time for treatment, causing irreparable losses to society, families and individuals

[0013] Thirdly, since the joint decision-making emphasizes the full explanation and description of the treatment plan by the doctor, the expression and evaluation of the patient's own demands, and the agreement between the doctor and the patient after many times of full communication and discussion, it is bound to consume a lot of time. Time, this decision-making mode can be implemented in patients considering whether to undergo elective treatment (such as elective orthopedic surgery), but for patients with acute cerebral infarction, from the onset of the disease to the administration of intravenous thrombolytic drugs (including hospital visit time, examination and testing) time, diagnosis time, thrombolysis evaluation time, and doctor-patient communication and decision-making time of informed consent) generally cannot exceed 4.5 hours, and no more than 6 hours at the latest. Obviously, the joint decision-making mode cannot be completed in a short time, which has become a constraint The biggest bottleneck in carrying out in patients with cerebral infarction

Images